{"database":"GEO","file_versions":[{"headers":{"Content-Type":["application/json"]},"body":{"files":{"Other":["ftp://ftp.ncbi.nlm.nih.gov/geo/series/GSE265nnn/GSE265947/"]},"type":"primary"},"statusCode":"OK","statusCodeValue":200}],"scores":null,"additional":{"omics_type":["Transcriptomics"],"species":["Homo sapiens"],"gds_type":["Expression profiling by high throughput sequencing"],"full_dataset_link":["https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE265947"],"repository":["GEO"],"entry_type":["GSE"],"additional_accession":[]},"is_claimable":false,"name":"Distinct cytokines regulate gene expression and anti-tumor activity in regenerated CD8+ T cells derived-from induced pluripotent stem cells.","description":"Adoptive T cell therapy can induce tumor regression in cancer patients. Tumor-specific CD8+ T cells regenerated from induced pluripotent stem cells (iPSCs), termed regenerated cytotoxic T lymphocytes (CTLs), are promising resources for adoptive T cell therapy. However, it remained unclear what kinds of cytokines enhance the anti-tumor activity of regenerated CTLs. In this study, we examined the effects of exogenous cytokines on the characteristics of regenerated CTLs. We found that IL-15- or IL-21-treatment in vitro enhanced the anti-tumor activity of regenerated CTLs, presumably by different mechanisms. IL-15-treated regenerated CTLs showed early-effector-like characteristics, whereas IL-21-treated regenerated CTLs showed both naïve- and effector-like characteristics. These findings provide useful insights for the clinical application of regenerated CTLs in the future.","dates":{"publication":"2026/04/02"},"accession":"GSE265947","cross_references":{"GSM":["GSM8232426","GSM8232427","GSM8232433","GSM8232434","GSM8232431","GSM8232432","GSM8232430","GSM8232428","GSM8232429"],"GPL":["24676"],"GSE":["265947"],"taxon":["Homo sapiens"]}}